Unknown

Dataset Information

0

INSTIs and NNRTIs Potently Inhibit HIV-1 Polypurine Tract Mutants in a Single Round Infection Assay.


ABSTRACT: Integrase strand transfer inhibitors (INSTIs) are a class of antiretroviral compounds that prevent the insertion of a DNA copy of the viral genome into the host genome by targeting the viral enzyme integrase (IN). Dolutegravir (DTG) is a leading INSTI that is given, usually in combination with nucleoside reverse transcriptase inhibitors (NRTIs), to treat HIV-1 infections. The emergence of resistance to DTG and other leading INSTIs is rare. However, there are recent reports suggesting that drug resistance mutations can occur at positions outside the integrase gene either in the HIV-1 polypurine tract (PPT) or in the envelope gene (env). Here, we used single round infectivity assays to measure the antiviral potencies of several FDA-approved INSTIs and non-nucleoside reverse transcriptase inhibitors (NNRTIs) against a panel of HIV-1 PPT mutants. We also tested several of our promising INSTIs and NNRTIs in these assays. No measurable loss in potency was observed for either INSTIs or NNRTIs against the HIV-1 PPT mutants. This suggests that HIV-1 PPT mutants are not able, by themselves, to confer resistance to INSTIs or NNRTIs.

SUBMITTER: Smith SJ 

PROVIDER: S-EPMC8705849 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

INSTIs and NNRTIs Potently Inhibit HIV-1 Polypurine Tract Mutants in a Single Round Infection Assay.

Smith Steven J SJ   Ferris Andrea A   Zhao Xuezhi X   Pauly Gary G   Schneider Joel P JP   Burke Terrence R TR   Hughes Stephen H SH  

Viruses 20211214 12


Integrase strand transfer inhibitors (INSTIs) are a class of antiretroviral compounds that prevent the insertion of a DNA copy of the viral genome into the host genome by targeting the viral enzyme integrase (IN). Dolutegravir (DTG) is a leading INSTI that is given, usually in combination with nucleoside reverse transcriptase inhibitors (NRTIs), to treat HIV-1 infections. The emergence of resistance to DTG and other leading INSTIs is rare. However, there are recent reports suggesting that drug r  ...[more]

Similar Datasets

| S-EPMC4754833 | biostudies-literature
| S-EPMC5766924 | biostudies-literature
| S-EPMC10928719 | biostudies-literature
| S-EPMC8133820 | biostudies-literature
| S-EPMC4393142 | biostudies-literature
| S-EPMC145536 | biostudies-literature
| S-EPMC4957839 | biostudies-other
| S-EPMC8865006 | biostudies-literature
| S-EPMC10039815 | biostudies-literature
| S-EPMC2377446 | biostudies-literature